Stay updated on Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial
Sign up to get notified when there's something new on the Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial page.

Latest updates to the Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe revision label on the page updated from v3.5.3 to v3.5.4, indicating a software update to the site's interface.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe page’s footer revision indicator was updated from v3.5.0 to v3.5.3, reflecting a change in the site/version display rather than any study information.SummaryDifference0.0%

- Check50 days agoChange DetectedThe study results section now includes posted results data (ORR by RECIST v1.1 with 18-month follow-up) and related dates/documents, and Cohort 3 has been renamed from 'Safety and Tolerability' to 'Tolerability' with a 100-day dosing assessment.SummaryDifference2%

- Check65 days agoChange DetectedResults Submitted is now displayed and the page revision updated to v3.5.0, replacing the previous No Results Posted and revision v3.4.3.SummaryDifference0.1%

- Check79 days agoChange DetectedRevision updated: from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check100 days agoChange DetectedAdded Fallopian tube cancer to the listed conditions and introduced the Genetic and Rare Diseases Information Center as a resource; updated page revision from v3.4.1 to v3.4.2.SummaryDifference0.2%

Stay in the know with updates to Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial page.